REDWOOD CITY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced it has regained compliance with Nasdaq listing requirements.
In a letter dated March 1, 2018, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule, the market value of publicly held shares rule and the market value of listed securities rule, as required by the Nasdaq Hearings Panel’s decision dated January 17, 2018, and is in compliance with other applicable requirements as set forth in the decision and required for listing on the Nasdaq Capital Market.
“Being a Nasdaq Capital Market listed company is an important part of Avinger’s corporate strategy,” commented Jeff Soinski, Avinger’s president and CEO. “The Company’s board and senior management team have worked diligently to ensure continued Nasdaq compliance. We appreciate the ongoing support of our shareholders through this process.”
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, CA. For more information, please visit www.avinger.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding continued compliance with Nasdaq listing requirements. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; our ability to demonstrate the benefits of our Lumivascular platform; the resource requirements related to Pantheris; the outcome of clinical trial results; potential exposure to third-party product liability, intellectual property and other litigation; lack of long-term data demonstrating the safety and efficacy of our Lumivascular platform products; experiences of high-volume users of our products may lead to better patient outcomes than those of physicians that are less proficient; reliance on third-party vendors; dependency on physician adoption; reliance on key personnel; and requirements to obtain regulatory approval to commercialize our products; as well as the other risks described in the section entitled “Risk Factors” and elsewhere in our quarterly Form 10-Q filing made with the Securities and Exchange Commission on November 14, 2017. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.
Public Relations Contact
VP of Marketing & Business Operations
Chief Business Officer and CFO